Revolution Medicines, Inc. SEC filings RVMD
Revolution Medicines, Inc. has 863 filings in SEC EDGAR's recent list, going back to Dec 21, 2016. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Apr 15, 2026 | — |
| 424B5 | Prospectus supplement | Apr 15, 2026 | — |
| FWP | Free writing prospectus | Apr 15, 2026 | — |
| 424B5 | Prospectus supplement | Apr 13, 2026 | — |
| 424B5 | Prospectus supplement | Apr 13, 2026 | — |
| 424B5 | Prospectus supplement | Feb 25, 2026 | — |
| S-8 | Employee stock plan registration | Feb 25, 2026 | — |
| S-8 | Employee stock plan registration | Feb 26, 2025 | — |
| 424B5 | Prospectus supplement | Dec 5, 2024 | — |
| FWP | Free writing prospectus | Dec 4, 2024 | — |
| 424B5 | Prospectus supplement | Dec 2, 2024 | — |
| 424B5 | Prospectus supplement | Aug 7, 2024 | — |
| S-3ASR | Automatic shelf registration | May 8, 2024 | — |
| S-3ASR | Automatic shelf registration | Mar 4, 2024 | — |
| S-8 | Employee stock plan registration | Feb 26, 2024 | — |
| 424B3 | Prospectus | Sep 29, 2023 | — |
| S-4/A | Filing | Sep 27, 2023 | — |
| S-4 | Registration for a merger or exchange | Sep 13, 2023 | — |
| 424B5 | Prospectus supplement | Mar 3, 2023 | — |
| 424B5 | Prospectus supplement | Mar 1, 2023 | — |
| S-8 | Employee stock plan registration | Feb 27, 2023 | — |
| 424B5 | Prospectus supplement | Jul 20, 2022 | — |
| 424B5 | Prospectus supplement | Jul 19, 2022 | — |
| S-8 | Employee stock plan registration | Feb 28, 2022 | — |
| 424B5 | Prospectus supplement | Nov 10, 2021 | — |
| S-8 | Employee stock plan registration | Mar 2, 2021 | — |
| S-3ASR | Automatic shelf registration | Mar 2, 2021 | — |
| 424B4 | Prospectus | Feb 5, 2021 | — |
| S-1MEF | Filing | Feb 3, 2021 | — |
| S-1/A | Amended registration statement | Feb 3, 2021 | — |
| S-1 | Registration statement | Feb 1, 2021 | — |
| 424B4 | Prospectus | Jul 10, 2020 | — |
| S-1 | Registration statement | Jul 6, 2020 | — |
| S-8 | Employee stock plan registration | Feb 18, 2020 | — |
| 424B4 | Prospectus | Feb 13, 2020 | — |
| S-1/A | Amended registration statement | Feb 11, 2020 | — |
| S-1/A | Amended registration statement | Feb 3, 2020 | — |
| S-1 | Registration statement | Jan 17, 2020 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RVMD (Nasdaq), RVMDW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Redwood City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1628171
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.